Sabby Management, LLC Bria Cell Therapeutics Corp. Transaction History

Sabby Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.28 - $6.73 $351,388 - $552,533	-82,100 Reduced 87.34%	11,905 $52,000
Q3 2022 Nov 14, 2022	BUY	$3.0 - $8.31 $109,248 - $302,616	36,416 Added 63.23%	94,005 $528,000
Q2 2022 Aug 15, 2022	BUY	$4.28 - $11.9 $118,243 - $328,761	27,627 Added 92.21%	57,589 $332,000
Q1 2022 May 16, 2022	BUY	$5.91 - $10.14 $177,075 - $303,814	29,962 New	29,962 $304,000
Q3 2021 Nov 15, 2021	SELL	$4.4 - $9.28 $862,545 - $1.82 Million	-196,033 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.89 - $6.57 $103,609 - $235,541	35,851 Added 22.38%	196,033 $1.05 Million
Q1 2021 May 17, 2021	BUY	$3.15 - $6.17 $504,573 - $988,322	160,182 New	160,182 $618,000

Ticker BCTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,518,000
Market Cap $9.31M
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.